Iron Polymaltose Complex
PreclinicalSmall molecule
Iron Polymaltose Complex is one of 34 small molecule programs targeting Iron deficiency anemia. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
85 competitors in Iron Deficiency Anemia
#DrugCompanyPhaseTrials
1Injectafer
AAmerican Regent, Inc.
Approved
Feraheme
AAzurity Pharmaceuticals
Approved
Niacor
AbbVieApproved
Folvite
Eli LillyApproved
Cecon
MMcGuff Pharmaceuticals, Inc.
Approved
Venofer
AAmerican Regent, Inc.
Phase 3
Dexferrum
NNew River Pharmaceuticals
Phase 3
Auryxia
KKeryx Biopharmaceuticals
Phase 3
Iron
WWatson Pharmaceuticals
Phase 3
IV Iron
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Iron Polymaltose Complex. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- DDr Salaha Azam